Research use only

Sold out · depth page

PT-141 — recent literature (RUO)

Bremelanotide analytical and receptor literature, 2023–2026

PT-141 10 mg · literature note

For laboratory research use only. Not for human or veterinary use, consumption, compounding into a medicine, or injection. Not authorized by Health Canada. Literature on this page is scientific context only. This page is not a licensed drug, a wellness protocol, or a dosing guide. Analytical and receptor-research framing only. This research material is not a licensed bremelanotide product.

Keep LC-HRMS degradant work and glioblastoma cell-model agonist activity as analytical and receptor context. This page is not consumer marketing.

How to read recent hits

Yuvaraaj et al. (2026) characterizes bremelanotide acetate and degradants by LC-HRMS/MS. Suzuki et al. (2024) reports melanocortin-receptor agonist activity in glioblastoma cell models. Molinoff et al. (2003) and Pfaus et al. (2022) remain the pharmacology and pathway anchors, as literature context only.

Analytical and cell-model papers do not authorize a human-use claim. This page does not claim current stock.

Identity

Form

Lyophilized powder, sealed vial

Strength

10 mg lyophilized vial (listed)

Purity

≥99% HPLC

CAS

  • Bremelanotide: 189691-06-3

PubMed

Selected literature

  • PMID 12851303 (2003) Molinoff et al., Annals of the New York Academy of Sciences — PT-141 melanocortin-agonist pharmacology
  • PMID 33455598 (2022) Pfaus et al., CNS Spectrums — bremelanotide and melanocortin pathway literature (context only)

Recent literature (2023–2026)

  • PMID 42485063 (2026) Yuvaraaj et al., Analytical Methods — LC-HRMS/MS characterization of bremelanotide acetate and degradants
  • PMID 39197897 (2024) Suzuki et al., Anticancer Research — bremelanotide melanocortin-receptor agonist activity in glioblastoma cell models

Literature is scientific context only. A paper does not make a research vial into a licensed medicine.

Bench reconstitution

When a lot is released to the bench, dissolve the lyophilized PT-141 cake in bacteriostatic water to the mg/mL the protocol specifies. Swirl gently; do not vortex. Record concentration and solvent lot. This page does not claim a vial is available. The volume is laboratory dilution, not a clinical dose.

Diluent page: bacteriostatic water.

Storage

Keep the lyophilized vial at 2–8 °C, protected from light and moisture, until the bench protocol calls for it. After reconstitution, hold at 2–8 °C; use within the sterility window your laboratory controls allow. Do not freeze–thaw repeatedly. Record open date and concentration in the notebook. Confirm the lot COA before you adopt a hold time.

Certificate of analysis

Every product has a View COA button. Where the lot certificate of analysis (identity and HPLC purity) is posted, it opens the certificate with a PDF download. Where it is not posted yet, the same button sends a request by email to request@pharmapeptidesrx.com, or you can write that address with the SKU. This page is not a COA.

Lab FAQ

Do analytical or cell-model papers authorize human-use claims?

No. Papers remain literature context for research-use-only procurement. Write request@pharmapeptidesrx.com to be notified when PT-141 returns. This page does not publish prices or banking details. Invoices go out from request@ only.

In this library

Sold out

Notify on restock

This lot is sold out. Write request@pharmapeptidesrx.com and we email you when it is back.